Design Therapeutics (DSGN) Competitors $3.90 -0.11 (-2.74%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$3.90 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DSGN vs. PHVS, CRMD, AKBA, OCS, LENZ, PRAX, ZYME, CMRX, CDMO, and NUVBShould you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Pharvaris (PHVS), CorMedix (CRMD), Akebia Therapeutics (AKBA), Oculis (OCS), LENZ Therapeutics (LENZ), Praxis Precision Medicines (PRAX), Zymeworks (ZYME), Chimerix (CMRX), Avid Bioservices (CDMO), and Nuvation Bio (NUVB). These companies are all part of the "pharmaceutical products" industry. Design Therapeutics vs. Its Competitors Pharvaris CorMedix Akebia Therapeutics Oculis LENZ Therapeutics Praxis Precision Medicines Zymeworks Chimerix Avid Bioservices Nuvation Bio Pharvaris (NASDAQ:PHVS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk, community ranking and dividends. Does the media refer more to PHVS or DSGN? In the previous week, Pharvaris had 20 more articles in the media than Design Therapeutics. MarketBeat recorded 21 mentions for Pharvaris and 1 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 1.68 beat Pharvaris' score of 0.62 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Pharvaris Positive Design Therapeutics Very Positive Which has more risk & volatility, PHVS or DSGN? Pharvaris has a beta of -2.86, meaning that its share price is 386% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Which has higher earnings & valuation, PHVS or DSGN? Pharvaris is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharvarisN/AN/A-$109.18M-$3.01-5.66Design TherapeuticsN/AN/A-$66.86M-$0.99-3.94 Do institutionals & insiders hold more shares of PHVS or DSGN? 56.6% of Design Therapeutics shares are held by institutional investors. 11.8% of Pharvaris shares are held by company insiders. Comparatively, 31.2% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in PHVS or DSGN? Pharvaris received 30 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 67.80% of users gave Pharvaris an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote. CompanyUnderperformOutperformPharvarisOutperform Votes4067.80% Underperform Votes1932.20% Design TherapeuticsOutperform Votes1033.33% Underperform Votes2066.67% Do analysts rate PHVS or DSGN? Pharvaris presently has a consensus price target of $36.20, indicating a potential upside of 112.32%. Design Therapeutics has a consensus price target of $4.00, indicating a potential upside of 2.56%. Given Pharvaris' stronger consensus rating and higher probable upside, equities research analysts plainly believe Pharvaris is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharvaris 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Design Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is PHVS or DSGN more profitable? Design Therapeutics' return on equity of -18.01% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets PharvarisN/A -38.52% -36.69% Design Therapeutics N/A -18.01%-17.38% SummaryDesign Therapeutics beats Pharvaris on 9 of the 15 factors compared between the two stocks. Get Design Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DSGN vs. The Competition Export to ExcelMetricDesign TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$221.40M$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-4.598.7827.1420.06Price / SalesN/A255.64411.98157.10Price / CashN/A65.8538.2534.64Price / Book0.796.557.064.70Net Income-$66.86M$143.93M$3.23B$247.88M7 Day Performance-2.50%3.84%2.85%2.63%1 Month Performance7.73%11.20%9.06%6.36%1 Year Performance3.45%4.18%31.43%14.05% Design Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DSGNDesign Therapeutics0.7089 of 5 stars$3.90-2.7%$4.00+2.6%-3.2%$221.40MN/A-4.5940Positive NewsGap UpPHVSPharvaris1.4579 of 5 stars$16.49-0.7%$40.67+146.6%+7.4%$862.26MN/A-5.8930Trending NewsAnalyst ForecastAnalyst RevisionGap UpCRMDCorMedix0.5757 of 5 stars$12.70+4.6%$15.00+18.1%+188.9%$861.38M$82.55M-15.6830Positive NewsAKBAAkebia Therapeutics4.4693 of 5 stars$3.25+7.3%$6.63+103.8%+221.6%$853.57M$184.91M-14.13430High Trading VolumeOCSOculis1.7955 of 5 stars$19.22-1.2%$31.50+63.9%+64.7%$839.18M$980K-9.962Positive NewsShort Interest ↑Analyst RevisionLENZLENZ Therapeutics1.6954 of 5 stars$29.16-0.1%$46.60+59.8%+58.1%$820.74MN/A-16.47110Positive NewsPRAXPraxis Precision Medicines2.5668 of 5 stars$39.82+3.3%$109.90+176.0%+13.2%$811.09M$8.12M-3.87110ZYMEZymeworks1.9055 of 5 stars$11.64+1.8%$21.00+80.4%+34.0%$809.88M$93.38M-7.76460Positive NewsCMRXChimerix0.7182 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.877 of 5 stars$12.50+0.1%$12.25-2.0%+56.4%$799.18M$139.91M-5.23320High Trading VolumeNUVBNuvation Bio3.0003 of 5 stars$2.34+10.1%$7.83+235.5%-22.5%$794.51M$10.96M-1.0860Trending NewsAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies PHVS Alternatives CRMD Alternatives AKBA Alternatives OCS Alternatives LENZ Alternatives PRAX Alternatives ZYME Alternatives CMRX Alternatives CDMO Alternatives NUVB Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DSGN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Design Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Design Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DSGN Stock Free DSGN Stock Alerts